BioSpace News Archive

RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, chief executive officer, will present a company overview during the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 at the Lotte New York Palace hotel in New York.

Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced that Dr. Hitto Kaufmann has been appointed as Hansa’s Chief Scientific Officer effective 1 December 2023.

Hugel, a global total medical aesthetics company, announced that the company resubmitted the BLA for its botulinum toxin, Letybo (letibotulinumtoxinA) on August 31st (local time), for the indication of glabellar (frown) lines to the U.S. FDA.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023.

Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial results for the six months ended June 30, 2023 (“the period”).

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company) developing a new class of synthetic anti-infectives, is pleased to report further patient case studies utilizing its lead anti-infective candidate, RECCE® 327.

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease (GD).

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 12, 2023 at 11:30 a.m. ET.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that effective , Dr. Suzanne Lentzsch has joined the Nexcella Scientific Advisory Board.